Iambic Therapeutics has filed to go public and says it could move IAM1363, its lead drug targeting HER2 cancers, into a ...
FDA warns Empower Pharmacy for 3rd time over GLP-1 drugs tirzepatide & semaglutide, citing copies of brand-name treatments & ...
USTR hears testimony for and against tariffs on German-made drugs as nine European pharma chairs press EU governments on ...
Insurers plan to significantly increase AI budgets from 6% in 2024 to 31% in 2026, per Define Ventures' Lynne Chou O'Keefe, ...
Viking Therapeutics' VK2735 patients maintained 85% of weight loss after switching to monthly dosing. Shares rose 20%. Phase 3 programs advancing; oral trial launching soon.
“In some ways, it’s good that it’s out there now, and now we have a working plan to work towards quarter by quarter,” the ...
Vertex's inaxaplin showed 42.7% UACR reduction in AMKD patients with modest proteinuria. AMPLITUDE enrollment complete; ...
ARPA-H's Advocate program funds AI systems for heart failure care, with Kaiser Permanente, Duke, Atman Health & UpDoc, facing trust & safety hurdles.
Celldex's barzolvolimab hits the mark in two Phase 3 chronic hives trials, but two anaphylaxis cases send shares down 12%.
Roche says its enicepatide hit weight and blood sugar goals in a Phase 2 diabetes trial, with the top dose driving 15.5% weight loss.
FDA approves IntraBio's Aqneursa for ataxia in ataxia-telangiectasia; Alkermes posts Phase 1b ADHD data; Biokin banks $250M ...
Pfizer and Lilly's MFN contracts with HHS show the drugmakers agreed to share revenue from higher overseas prices with the government.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results